扩散张量成像与动态磁敏感对比增强MRI预测脑转移瘤患者总生存期
本研究回顾性分析101例治疗前脑转移瘤患者的DTI参数(MD、FA、CL、CP、CS)及DSC-PWI的rCBVmax,基于优势病灶强化区定量,按最佳截点分组行生存分析。单因素分析显示MDmin、FA、CL、CP与mOS显著相关,rCBVmax呈边缘显著;多因素分析最佳模型含MDmin、rCBVmax、RPA及病灶数。组织病理学亚组提示间质含量高者mOS更差。
要点
- 治疗前脑转移瘤强化区的MDmin和rCBVmax与总生存期相关,可辅助预后分层。
- 多因素模型纳入MDmin、rCBVmax、RPA和病灶数,其中RPA预测力最强。
- 高间质含量的转移瘤mOS更差,可能解释DTI与灌注参数的预后差异。
核心结论
- 治疗前DTI参数尤其是MDmin和rCBVmax是脑转移瘤总生存期预后的有前景影像标志物。
- 间质细胞丰富度可能是导致DTI与灌注参数预后差异的因素之一。
研究设计与样本
- 回顾性研究,纳入101例治疗前脑转移瘤患者,行DTI和DSC-PWI检查。
- 采用半自动分割在优势转移灶强化区定量DTI参数(MD、FA、CL、CP、CS)和rCBVmax。
- 按各参数最佳系数和百分位数将患者分为短期与长期生存组,行Kaplan-Meier及多因素生存分析。
- 对10例亚组行组织病理学对照分析,比较DTI参数与rCBVmax两端患者的间质含量。
关键影像表现/征象
- DTI参数MDmin、FA、CL、CP在短期与长期生存组间mOS差异显著,rCBVmax呈边缘显著(p=0.07)。
- 组织病理学显示转移瘤间质含量随DTI参数与rCBVmax组合不同而存在显著差异,高间质含量者mOS更差。
诊断标准与关键数值
- 单因素分析:MDmin(p<0.05)、FA(p<0.01)、CL(p<0.05)、CP(p<0.01)与mOS显著相关,rCBVmax(p=0.07)呈边缘显著。
- 多因素分析最佳预测模型包含MDmin(p=0.05)、rCBVmax(p<0.05)、RPA(p<0.0001)和病灶数(p=0.07)。
临床应用与阅片要点
- 阅片时可关注优势脑转移灶强化区的MDmin和rCBVmax,结合RPA和病灶数用于预后分层参考。
- DTI与DSC-PWI参数可为治疗决策提供额外临床指导,但需结合常规预后因素综合判断。
局限性
- 回顾性研究设计,样本量101例,组织病理学验证仅10例亚组。
- rCBVmax在单因素分析中仅呈边缘显著(p=0.07),预后价值需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the prognostic utility of DTI and DSC-PWI perfusion-derived parameters in brain metastases patients.
METHODS: Retrospective analyses of DTI-derived parameters (MD, FA, CL, CP, and CS) and DSC-perfusion PWI-derived rCBVmax from 101 patients diagnosed with brain metastases prior to treatment were performed. Using semi-automated segmentation, DTI metrics and rCBVmax were quantified from enhancing areas of the dominant metastatic lesion. For each metric, patients were classified as short- and long-term survivors based on analysis of the best coefficient for each parameter and percentile to separate the groups. Kaplan-Meier analysis was used to compare mOS between these groups. Multivariate survival analysis was subsequently conducted. A correlative histopathologic analysis was performed in a subcohort (n = 10) with DTI metrics and rCBVmax on opposite ends of the spectrum.
RESULTS: Significant differences in mOS were observed for MDmin (p < 0.05), FA (p < 0.01), CL (p < 0.05), and CP (p < 0.01) and trend toward significance for rCBVmax (p = 0.07) between the two risk groups, in the univariate analysis. On multivariate analysis, the best predictive survival model was comprised of MDmin (p = 0.05), rCBVmax (p < 0.05), RPA (p < 0.0001), and number of lesions (p = 0.07). On histopathology, metastatic tumors showed significant differences in the amount of stroma depending on the combination of DTI metrics and rCBVmax values. Patients with high stromal content demonstrated poorer mOS.
CONCLUSION: Pretreatment DTI-derived parameters, notably MDmin and rCBVmax, are promising imaging markers for prognostication of OS in patients with brain metastases. Stromal cellularity may be a contributing factor to these differences.
ADVANCES IN KNOWLEDGE: The correlation of DTI-derived metrics and perfusion MRI with patient outcomes has not been investigated in patients with treatment naïve brain metastasis. DTI and DSC-PWI can aid in therapeutic decision-making by providing additional clinical guidance.
引用
- de Godoy, Chen, Chawla, et al. Prognostication of overall survival in patients with brain metastases using diffusion tensor imaging and dynamic susceptibility contrast-enhanced MRI. Br J Radiol. 2022. PMID: 36354164. doi:10.1259/bjr.20220516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。